GLP-1 Companion Supplements Are Booming. So Is the Compliance Risk.
The GLP-1 companion supplement market is set to nearly triple by 2034, and regulators are already scrutinizing how brands describe what these products do.
What GLP-1 companion supplements are actually built to do
A GLP-1 companion supplement is any product formulated around the side effects of drugs like Ozempic, Wegovy, and Mounjaro rather than the drug's effect itself. When someone eats less, their intake of protein, fiber, and micronutrients drops with it, and muscle loss follows the weight loss. So the category has filled in fast: whey and collagen blends built for smaller serving sizes, fiber and electrolyte formulas, multivitamins positioned for people whose appetite has changed. It's less a new ingredient story than a new occasion for old categories.
The category is growing faster than most of CPG right now
Straits Research puts the GLP-1 supplement market at roughly $2 billion in 2025, on track to reach $5.52 billion by 2034, a CAGR near 12%. Legacy brands moved quickly to claim shelf space: Herbalife launched a dedicated GLP-1 Nutrition Companion line, The Vitamin Shoppe rolled out a GLP-1 Support Protein built around whey, collagen, and muscle-preserving compounds, and smaller supplement houses followed with their own versions within months. The demand is real. ADM's 2025 consumer research found 83% of GLP-1 users were interested in nutrition products built specifically for their situation, with muscle retention the priority named most often.
Why is GLP-1 marketing under so much regulatory scrutiny?
Because the acronym is doing a lot of unearned work. Through 2026, the FDA issued repeated rounds of warning letters over misleading claims tied to compounded GLP-1 drugs, and that scrutiny has started to brush up against supplement marketing too. BBB National Programs opened an inquiry into Ryze Superfoods over "appetite suppressing" language on a mushroom-based product, and the company agreed to drop the claim. Doctors and consumer groups have since pushed regulators for a clear standard on what a food or supplement label can say about GLP-1 at all. The legal line, per industry guidance, is narrow but real: a supplement can support the nutritional gaps GLP-1 use creates, but it cannot imply it replicates, enhances, or replaces the drug's pharmacological effect.
What disciplined GLP-1 branding actually looks like
The safer, and frankly more credible, claims read like "supports muscle maintenance with exercise" or "supports daily protein intake," not language that borrows the drug's authority. That's a packaging and copy decision as much as a legal one: label hierarchy, front-of-pack claims, and site copy all have to say the same disciplined thing, because a regulator or a skeptical customer will read them as one system, not three separate documents. This is the system-first case in its plainest form. A brand that treats claims review as a late-stage legal pass, after the label is designed and the site copy is written, is building the risk in rather than out.
The brands that hold up in this category over the next few years won't be the ones that lean hardest on the letters G-L-P-1. They'll be the ones whose packaging, labeling, and copy were built together, disciplined enough to earn the claim they're actually allowed to make.
Have a project in mind?
Tell us what you're making. Half-formed idea, full-blown launch, or somewhere in between — we're happy to talk it through.
